Last reviewed · How we verify
Candesartan, Amlodipine, Atorvastatin
Candesartan, Amlodipine, Atorvastatin is a Small molecule drug developed by Midas Pharma GmbH. It is currently in Phase 1 development.
At a glance
| Generic name | Candesartan, Amlodipine, Atorvastatin |
|---|---|
| Sponsor | Midas Pharma GmbH |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Canadian Prevention of Renal and Cardiovascular Endpoints Trial (NA)
- Drug-drug-interaction Study of Candesartan, Amlodipine and Atorvastatin (PHASE1)
- Benefits of Medical Therapy Plus Stenting for Renal Atherosclerotic Lesions (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Candesartan, Amlodipine, Atorvastatin CI brief — competitive landscape report
- Candesartan, Amlodipine, Atorvastatin updates RSS · CI watch RSS
- Midas Pharma GmbH portfolio CI
Frequently asked questions about Candesartan, Amlodipine, Atorvastatin
What is Candesartan, Amlodipine, Atorvastatin?
Candesartan, Amlodipine, Atorvastatin is a Small molecule drug developed by Midas Pharma GmbH.
Who makes Candesartan, Amlodipine, Atorvastatin?
Candesartan, Amlodipine, Atorvastatin is developed by Midas Pharma GmbH (see full Midas Pharma GmbH pipeline at /company/midas-pharma-gmbh).
What development phase is Candesartan, Amlodipine, Atorvastatin in?
Candesartan, Amlodipine, Atorvastatin is in Phase 1.